Breast CancerNCT06238453
The Effect of Training Given by Whatsapp Application on Mamography Health Beliefs and Behaviors
An observational study of Breast Cancer, run by Kemal Yaran.
Trial summary
It is known that the healing process of breast cancer is accelerated thanks to the early diagnosis and effective treatment. Mammography screening is an important diagnostic method in the early diagnosis of breast cancer. Read more about this study
- Who is it for?
- Ages 40 to 69 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Breast Cancer
- How many people
- 134 participants
- Where
- No sites listed yet
- Study dates
- 12 Feb 2024to 10 Aug 2024
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 69 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: The population of the study will consist of women who have applied to Erzurum Cancer Early Diagnosis, Screening and Training Center before, had mammography and phone records, whose appointment has been made since December 2022, and who meet the sampling selection criteria.
Who may be able to join
- Be between the ages of 40-69,
- Be woman,
- Not having been diagnosed with breast cancer,
- Not to be pregnant, lactating or puerperal,
- Absence of a mental illness
- At least 2 years have passed since the last mammogram,
- Being able to use the WhatsApp application
Who cannot join
- Having had problems with breast cancer before,
- Having a mammogram at regular intervals,
- Having had breast-conserving surgery for any purpose.
About this study
Official title: The Effect of Health Belief Model-based Education Given Through Whatsapp Application on Health Beliefs Regarding Mammography and Re-mammography
It is known that the healing process of breast cancer is accelerated thanks to the early diagnosis and effective treatment. Mammography screening is an important diagnostic method in the early diagnosis of breast cancer. It is thought that the education to be given according to the Health Belief Model will make important contributions to developing a positive attitude in breast cancer screenings and regular mammography.
Read the detailed description
The research will consist of women who have previously applied to Erzurum Cancer Early Diagnosis, Screening and Education Center, had mammography taken, and whose phone records are available, whose appointment has been made since December 2022, and who meet the screening selection criteria. Women who have had a mammography appointment from KETEM and have not taken it yet, request their phone information. After the women were searched one by one to identify those who fit their characteristics and volunteers, they would leave the simple random experiment control elements. During the searches, all women will be invited to KETEM to have a mammogram again. The experimental group will send educational content through the WhatsApp application once a week, and will also answer questions and provide individual counseling. A total of 8 weeks of intervention will be implemented, the first 6 weeks of training will be provided with training presentations and the last 2 weeks of training video will be sent. Feedback will be received after the training presentations are followed through the WhatsApp application where they are read. The control group will not take any action and will be invited to KETEM for mammography. Pre-test and post-analysis phone access will be collected. At the end of the training, he will have the final examinations applied after 3 months. The number of women who participated in the study will be determined by examining the KETEM records of mammography.
- Conditions
- Breast Cancer
- Keywords
- Breast Cancer, Health Belief Model, Mammography
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Educational content will be sent to the experimental group once a week via the WhatsApp application, and individual counseling will be provided by answering their questions at the same time. A total of 8 weeks of intervention will be implemented, training will be given with training presentations in the first 6 weeks and training videos will be sent in the last 2 weeks. | |
| Control group | The control group will be invited to KETEM to have a mammogram without any intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pre-test evaluation
The Health Belief Model Scale for Breast Cancer Screening and the Mammography Self-Efficacy Scale will be administered to all women in the experimental and control groups for pre-test purposes. There is no overall total score of the Health Belief Model Scale on Breast Cancer Screenings. Each sub-dimension's own total score is evaluated. The scale is a Likert type scale scored from 1 to 5. The scoring of the scale ranges from 1 point for "strongly disagree" to 5 points for "strongly agree". Increasing scores obtained from sub-dimensions indicate that the perception of that sub-dimension is high. Mammography Self-Efficacy Scale has ten items and five-point Likert type. The scale answers "strongly disagree" are evaluated as 1 point, "disagree" as 2 points, "undecided" as 3 points, "agree" as 4 points and "strongly agree" as 5 points. A higher score for each dimension indicates a higher probability of having a mammogram.
Measured: Three month
Posttest evaluation
Training presentations will be sent to the experimental group in the first 6 weeks and training videos will be sent in the last 2 weeks. A total of 8 weeks of intervention will be implemented. Training content will be sent via WhatsApp application once a week. No intervention will be made to the control group by the researchers during this period. Those in the control group will be invited to KETEM to have a mammogram. Three months after the training is completed, the Health Belief Model Scale for Breast Cancer Screening and the Mammography Self-Efficacy Scale will be administered to both groups for posttest purposes.
Measured: Six month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Feb 2024
- Study start12 Feb 2024 (estimated)
- Primary completion2 Apr 2024 (estimated)
- Study completion10 Aug 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 134 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Kemal Yaran
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Kemal Yaran, Muş Alparslan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06238453
- Sponsor's protocol ID
- B.30.2.ATA.0.01.00/681
- Status last verified
- Feb 2024
- First submitted
- 29 Dec 2023
- Last updated
- 2 Feb 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Health Belief Model-based Education Given Through Whatsapp Application on Health Beliefs Regarding Mammography and Re-mammography
- ClinicalTrials.gov ID
- NCT06238453
- Acronym / sponsor ID
- B.30.2.ATA.0.01.00/681
- Conditions
- Breast Cancer
- Keywords
- Breast Cancer, Health Belief Model, Mammography
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 134 participants (estimated)
- Lead sponsor
- Kemal YaranUniversity, hospital or other
- Study start
- 12 Feb 2024 (estimated)
- Primary completion
- 2 Apr 2024 (estimated)
- Study completion
- 10 Aug 2024 (estimated)
- First posted
- 2 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is known that the healing process of breast cancer is accelerated thanks to the early diagnosis and effective treatment. Mammography screening is an important diagnostic method in the early diagnosis of breast cancer. It is thought that the education to be given according to the Health Belief Model will make important contributions to developing a positive attitude in breast cancer screenings and regular mammography.
Detailed description
The research will consist of women who have previously applied to Erzurum Cancer Early Diagnosis, Screening and Education Center, had mammography taken, and whose phone records are available, whose appointment has been made since December 2022, and who meet the screening selection criteria. Women who have had a mammography appointment from KETEM and have not taken it yet, request their phone information. After the women were searched one by one to identify those who fit their characteristics and volunteers, they would leave the simple random experiment control elements. During the searches, all women will be invited to KETEM to have a mammogram again. The experimental group will send educational content through the WhatsApp application once a week, and will also answer questions and provide individual counseling. A total of 8 weeks of intervention will be implemented, the first 6 weeks of training will be provided with training presentations and the last 2 weeks of training video will be sent. Feedback will be received after the training presentations are followed through the WhatsApp application where they are read. The control group will not take any action and will be invited to KETEM for mammography. Pre-test and post-analysis phone access will be collected. At the end of the training, he will have the final examinations applied after 3 months. The number of women who participated in the study will be determined by examining the KETEM records of mammography.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental group | – | –Educational content will be sent to the experimental group once a week via the WhatsApp application, and individual counseling will be provided by answering their questions at the same time. A total of 8 weeks of intervention will be implemented, training will be given with training presentations in the first 6 weeks and training videos will be sent in the last 2 weeks. |
| Control group | – | –The control group will be invited to KETEM to have a mammogram without any intervention. |
Who may qualify
- Ages
- 40 to 69 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The population of the study will consist of women who have applied to Erzurum Cancer Early Diagnosis, Screening and Training Center before, had mammography and phone records, whose appointment has been made since December 2022, and who meet the sampling selection criteria.
Key inclusion criteria (7 listed)
- Be between the ages of 40-69,
- Be woman,
- Not having been diagnosed with breast cancer,
- Not to be pregnant, lactating or puerperal,
- Absence of a mental illness
Key exclusion criteria (3 listed)
- Having had problems with breast cancer before,
- Having a mammogram at regular intervals,
- Having had breast-conserving surgery for any purpose.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Pre-test evaluation
Time frame: Three month
The Health Belief Model Scale for Breast Cancer Screening and the Mammography Self-Efficacy Scale will be administered to all women in the experimental and control groups for pre-test purposes. There is no overall total score of the Health Belief Model Scale on Breast Cancer Screenings. Each sub-dimension's own total score is evaluated. The scale is a Likert type scale scored from 1 to 5. The scoring of the scale ranges from 1 point for "strongly disagree" to 5 points for "strongly agree". Increasing scores obtained from sub-dimensions indicate that the perception of that sub-dimension is high. Mammography Self-Efficacy Scale has ten items and five-point Likert type. The scale answers "strongly disagree" are evaluated as 1 point, "disagree" as 2 points, "undecided" as 3 points, "agree" as 4 points and "strongly agree" as 5 points. A higher score for each dimension indicates a higher probability of having a mammogram.
Posttest evaluation
Time frame: Six month
Training presentations will be sent to the experimental group in the first 6 weeks and training videos will be sent in the last 2 weeks. A total of 8 weeks of intervention will be implemented. Training content will be sent via WhatsApp application once a week. No intervention will be made to the control group by the researchers during this period. Those in the control group will be invited to KETEM to have a mammogram. Three months after the training is completed, the Health Belief Model Scale for Breast Cancer Screening and the Mammography Self-Efficacy Scale will be administered to both groups for posttest purposes.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2024.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer, run by Kemal Yaran.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pre-test evaluation (time frame: Three month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2024.